IFx-Hu2.0

N/A

Report date: 2026/04/18 20:00:19

Base Information

Drug NameIFx-Hu2.0
Drug Alias NameEmm55 Streptococcal antigen pDNApDNA Intralesional cancer vaccineAutologous whole-cell ImmuneFx™ cancer vaccine therapyIFx-Hu2.0IFx-2.0
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Nucleic acid vaccine > DNA vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsSkin NeoplasmsCarcinoma, Squamous CellCarcinoma, Basal Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesH Lee Moffitt Cancer Center & Research InstituteMorphogenesis Inc
China Registration ClassN/A

Develop Information

Active CompaniesH Lee Moffitt Cancer Center & Research InstituteKintara Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSkin NeoplasmsCarcinoma, Squamous CellCarcinoma, Basal Cell +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A